凯莱英(002821) - 2022 Q1 - 季度财报

Important Notice This section confirms the accuracy and completeness of the quarterly report, with assurances from the board, supervisors, and senior management, and notes that the report is unaudited - The company's board of directors, supervisory board, and senior management guarantee the truthfulness, accuracy, and completeness of the quarterly report, with no false records, misleading statements, or major omissions[4] - The company's responsible person, the person in charge of accounting work, and the head of the accounting department declare that the financial information in the quarterly report is true, accurate, and complete[4] - This first quarterly report for the current period is unaudited[4] Key Financial Data This section provides an overview of the company's financial performance and position, highlighting significant growth in revenue and net profit, along with changes in key financial indicators and their underlying reasons Key Accounting Data and Financial Indicators In Q1 2022, Asymchem Laboratories achieved significant financial growth, with substantial increases in operating revenue and net profit attributable to shareholders, alongside improved EPS and ROE Key Accounting Data and Financial Indicators | Indicator | Current Period (RMB) | Prior Year Period (RMB) | Change from Prior Year Period (%) | | :--- | :--- | :--- | :--- | | Operating Revenue | 2,061,708,856.14 | 777,189,276.45 | 165.28% | | Net Profit Attributable to Shareholders of the Listed Company | 499,398,084.81 | 154,330,479.55 | 223.59% | | Net Profit Attributable to Shareholders of the Listed Company After Deducting Non-recurring Gains and Losses | 486,390,519.38 | 129,442,396.10 | 275.76% | | Net Cash Flow from Operating Activities | 204,607,061.83 | 100,659,080.60 | 103.27% | | Basic Earnings Per Share (RMB / share) | 1.91 | 0.64 | 198.44% | | Diluted Earnings Per Share (RMB / share) | 1.90 | 0.64 | 196.88% | | Weighted Average Return on Net Assets | 3.88% | 2.14% | 1.74% | Key Financial Position Indicators | Indicator | End of Current Reporting Period (RMB) | End of Prior Year (RMB) | Change from End of Prior Year (%) | | :--- | :--- | :--- | :--- | | Total Assets | 16,389,663,097.90 | 15,156,297,270.34 | 8.14% | | Total Equity Attributable to Shareholders of the Listed Company | 13,514,177,861.13 | 12,610,011,324.42 | 7.17% | Non-recurring Gains and Losses Items and Amounts Non-recurring gains and losses for the current period primarily stemmed from government grants and fair value changes of financial assets, totaling 13,007,565.43 RMB Non-recurring Gains and Losses | Item | Amount for Current Period (RMB) | | :--- | :--- | | Government grants recognized in current profit or loss | 8,038,406.63 | | Gains and losses from changes in fair value of financial assets held for trading, financial liabilities held for trading, and investment income from disposal of financial assets held for trading, financial liabilities held for trading, and available-for-sale financial assets, excluding effective hedge accounting related to normal business operations | 10,284,400.30 | | Other non-operating income and expenses apart from the above | -3,009,096.40 | | Less: Income tax impact | 2,306,145.10 | | Total | 13,007,565.43 | Changes and Reasons for Key Accounting Data and Financial Indicators The company's strong Q1 2022 revenue and net profit growth were driven by its "dual-driver" strategy, rapid development of small molecule and emerging businesses, and full capacity utilization, with balance sheet and cash flow items also significantly impacted by business expansion and investment activities - In Q1 2022, the company's total operating revenue was 2.062 billion RMB, a 165.28% year-on-year increase, or 171.64% excluding exchange rate fluctuations[8] - Net profit attributable to shareholders was 499 million RMB, a 223.59% year-on-year increase, with adjusted net profit attributable to shareholders growing by 252.42%[8] - Strong revenue growth was attributed to the effective "dual-driver" strategy, with small molecule business growing 165.9% and emerging businesses by 157.4%, while chemical macromolecule, biological macromolecule, formulation, and clinical CRO revenues all increased by over 100%[9] - Operating costs increased by 154.23% concurrently, with gross margin showing an upward trend due to the company's full capacity utilization[9] - Administrative expenses increased by 65.28%, mainly due to increased headcount, salaries, and equity incentive expenses[9] - R&D expenses increased by 56.86%, primarily due to continuous investment in R&D and the development of technology innovation platforms[9][10] - Financial expenses increased by 775.43%, mainly due to exchange losses from currency fluctuations[10] - Investment income increased by 13369.67%, primarily from investment gains generated by the company's associate companies[10] - Cash paid for the acquisition of fixed assets, intangible assets, and other long-term assets increased by 173.40%, mainly due to increased orders, capacity expansion, and greater investment in plants and equipment[10] - Cash paid for investments increased by 7228.81%, primarily due to the purchase of wealth management products during the period[10] - Cash received from investments increased by 1369.86%, mainly due to the completion of H-share over-allotment proceeds during the period[10] Shareholder Information This section details the company's shareholder structure, including the total number of common shareholders and the holdings of the top ten shareholders at the end of the reporting period Total Number of Common Shareholders and Top Ten Shareholders' Holdings As of the end of the reporting period, the company had 26,675 common shareholders, with ASYMCHEM LABORATORIES, INCORPORATED being the largest shareholder at 33.48%, and HKSCC NOMINEES LIMITED holding 7.45% as an overseas legal entity - Total number of common shareholders at the end of the reporting period: 26,675[11] Top Ten Common Shareholders | Shareholder Name | Shareholder Nature | Shareholding Percentage (%) | Number of Shares Held | | :--- | :--- | :--- | :--- | | ASYMCHEM LABORATORIES, INCORPORATED | Overseas Legal Entity | 33.48% | 88,510,520 | | HKSCC NOMINEES LIMITED | Overseas Legal Entity | 7.45% | 19,680,900 | | Industrial and Commercial Bank of China Co., Ltd. - China Universal Medical & Healthcare Mixed Securities Investment Fund | Domestic Non-State-Owned Legal Entity | 4.53% | 11,987,613 | | Hong Kong Securities Clearing Company Limited | Overseas Legal Entity | 4.40% | 11,643,631 | | HAO HONG | Overseas Natural Person | 3.86% | 10,191,928 | | Tianjin Guorong Business Information Consulting Co., Ltd. | Domestic Non-State-Owned Legal Entity | 1.79% | 4,743,360 | | China Construction Bank Co., Ltd. - ICBC Credit Suisse Frontier Medical Stock Investment Fund | Domestic Non-State-Owned Legal Entity | 1.74% | 4,603,000 | | Bank of China Co., Ltd. - GF Medical & Healthcare Stock Investment Fund | Domestic Non-State-Owned Legal Entity | 1.27% | 3,349,025 | | Industrial and Commercial Bank of China Co., Ltd. - China Universal Medical Innovation Stock Investment Fund | Domestic Natural Person | 1.08% | 2,847,299 | | Bank of China Co., Ltd. - China Merchants Guozheng Biomedical Index Graded Securities Investment Fund | Domestic Non-State-Owned Legal Entity | 0.94% | 2,472,607 | - Mr. HAO HONG is the controlling shareholder and actual controller of ASYMCHEM LABORATORIES, INCORPORATED, and has an associated relationship with ASYMCHEM LABORATORIES, INCORPORATED[13] Total Number of Preferred Shareholders and Top 10 Preferred Shareholders' Holdings The company has no preferred shareholders - The company has no preferred shareholders[13] Other Important Matters This section outlines significant corporate events, including the listing of H-shares on the Hong Kong Stock Exchange and the subsequent exercise of the over-allotment option - The company's 18,415,400 H-shares were listed and traded on the Main Board of The Stock Exchange of Hong Kong Limited on December 10, 2021[14] - The company partially exercised its over-allotment option on January 2, 2022, involving a total of 1,265,500 H-shares, which were listed on the Main Board of the Hong Kong Stock Exchange on January 5, 2022[14] - Following the completion of this over-allotment, the company's total A+H share capital is 264,342,018 shares[14] Quarterly Financial Statements This section presents the consolidated balance sheet, income statement, and cash flow statement for Asymchem Laboratories for Q1 2022, providing a comprehensive view of its financial position, operating results, and cash flows Financial Statements This section presents the detailed consolidated financial statements for Q1 2022, including the balance sheet, income statement, and cash flow statement Consolidated Balance Sheet As of March 31, 2022, the company's total assets reached 16.39 billion RMB, an 8.14% increase from the beginning of the year, primarily due to increases in financial assets held for trading, prepayments, and fixed assets, with total liabilities and owner's equity also growing Consolidated Balance Sheet | Item | End of Period (RMB) | Beginning of Year (RMB) | | :--- | :--- | :--- | | Cash and Cash Equivalents | 5,642,739,406.29 | 6,234,457,167.58 | | Financial Assets Held for Trading | 887,856,000.00 | 401,198,333.33 | | Accounts Receivable | 2,051,597,484.61 | 1,816,200,714.43 | | Inventories | 1,707,564,369.77 | 1,396,115,127.88 | | Total Current Assets | 11,060,432,081.38 | 10,310,396,863.27 | | Fixed Assets | 2,613,729,469.76 | 2,243,835,516.94 | | Construction in Progress | 1,092,914,694.49 | 1,047,257,690.87 | | Total Assets | 16,389,663,097.90 | 15,156,297,270.34 | | Accounts Payable | 858,848,577.04 | 551,866,159.80 | | Total Current Liabilities | 2,491,414,488.95 | 2,204,806,672.76 | | Total Liabilities | 2,875,485,236.77 | 2,546,285,945.92 | | Total Equity Attributable to Owners of the Parent Company | 13,514,177,861.13 | 12,610,011,324.42 | | Total Liabilities and Equity | 16,389,663,097.90 | 15,156,297,270.34 | Consolidated Income Statement In Q1 2022, the company's total operating revenue increased by 165.28% to 2.062 billion RMB, and net profit grew by 223.59% to 499 million RMB, driven by strong business growth and effective cost and expense control Consolidated Income Statement | Item | Current Period (RMB) | Prior Period (RMB) | | :--- | :--- | :--- | | Total Operating Revenue | 2,061,708,856.14 | 777,189,276.45 | | Operating Cost | 1,128,892,034.57 | 444,047,380.18 | | Taxes and Surcharges | 9,815,688.11 | 7,375,051.12 | | Selling Expenses | 20,540,724.40 | 19,141,479.12 | | Administrative Expenses | 162,978,091.37 | 98,610,120.31 | | Research and Development Expenses | 130,883,695.56 | 83,440,733.89 | | Financial Expenses | 48,368,735.63 | -7,161,138.84 | | Investment Income | 11,660,530.17 | -87,873.58 | | Operating Profit | 570,097,662.75 | 165,152,871.37 | | Total Profit | 567,088,566.35 | 165,290,678.28 | | Income Tax Expense | 67,690,481.54 | 10,961,374.16 | | Net Profit | 499,398,084.81 | 154,329,304.12 | | Net Profit Attributable to Owners of the Parent Company | 499,398,084.81 | 154,330,479.55 | | Basic Earnings Per Share | 1.91 | 0.64 | | Diluted Earnings Per Share | 1.90 | 0.64 | Consolidated Cash Flow Statement In Q1 2022, net cash flow from operating activities increased by 103.27% to 205 million RMB, mainly due to increased sales collections; cash outflow from investing activities significantly rose due to wealth management product purchases and capacity expansion; and cash inflow from financing activities increased significantly due to H-share over-allotment proceeds Consolidated Cash Flow Statement | Item | Current Period (RMB) | Prior Period (RMB) | | :--- | :--- | :--- | | Net Cash Flow from Operating Activities | 204,607,061.83 | 100,659,080.60 | | Net Cash Flow from Investing Activities | -1,131,790,662.67 | -239,398,407.60 | | Net Cash Flow from Financing Activities | 383,841,586.32 | 10,625,287.78 | | Effect of Exchange Rate Changes on Cash and Cash Equivalents | -48,375,746.77 | -3,147,007.99 | | Net Increase in Cash and Cash Equivalents | -591,717,761.29 | -131,261,047.21 | | Cash and Cash Equivalents at End of Period | 5,642,739,406.29 | 1,990,297,803.19 | - Cash received from sales of goods and rendering of services increased by 102.89% year-on-year, indicating improved collections[10] - Cash paid for the acquisition of fixed assets, intangible assets, and other long-term assets increased by 173.40% year-on-year, primarily due to capacity expansion and increased investment in plants and equipment[10] - Cash paid for investments increased by 7228.81% year-on-year, mainly due to the purchase of wealth management products[10] - Cash received from investments increased by 1369.86% year-on-year, primarily due to the completion of H-share over-allotment proceeds[10] Audit Report This section explicitly states that Asymchem Laboratories' Q1 2022 report is unaudited - The company's first quarterly report is unaudited[24]